Immunogenicity and safety study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) vaccine (GSK-580299) and Merck's Gardasil vaccine when administered according to alternative 2-dose schedules in 9-14 year old females

Trial Identifier: 115411
Sponsor: GlaxoSmithKline
NCTID:: NCT01462357
Start Date: November 2011
Primary Completion Date: October 2015

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
French version was updated (31 Oct 2019)

Trial Locations

Country Location
France Dax, France, 40100
France Draguignan, France, 83300
France Essey les Nancy, France, 54270
France Le Havre, France, 76620
France Nice, France, 06300
France Paris cedex 20, France, 75970
France Rosiers d'Egletons, France, 19300
France Saint Cyr Sur Loir, France, 37540
France Seysses, France, 31600
France Tours, France, 37100
Hong Kong Pokfulam, Hong Kong
Hong Kong Shatin, Hong Kong
Singapore Singapore, Singapore, 169608
Singapore Singapore, Singapore, 529889
Singapore Singapore, Singapore, 228510
Singapore Singapore, Singapore, 768826
Singapore Singapore, Singapore, 229899
Singapore Singapore, Singapore, 119074
Sweden ESKILSTUNA, Sweden, SE-631 88
Sweden LINKÖPING, Sweden, SE-581 85
Sweden ÖREBRO, Sweden, SE-701 16